RESEARCH ARTICLE


Use of a Thrombin Fibrin Sealant in Reducing Blood Loss in Revision Hip Arthroplasty



Ali Ghoz 1, Hesham Al-Khateeb*, 2, Shanmugasundaram Rajkumar 2, Shawn Tavares 3, Antonio Andrade 3
1 Hinchingbrooke Hospital, Hinchingbrooke Park, Hinchingbrooke, Huntingdon, Cambridgeshire PE29 6NT, UK
2 Department of Trauma and Orthopaedics, King Hamad University Hospital, Bahrain
3 Royal Berkshire Hospital, Craven Rd, Reading RG1 5AN, UK


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 806
Abstract HTML Views: 857
PDF Downloads: 175
Total Views/Downloads: 1838
Unique Statistics:

Full-Text HTML Views: 534
Abstract HTML Views: 490
PDF Downloads: 113
Total Views/Downloads: 1137



© Ghoz et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Trauma and Orthopaedics, King Hamad University Hospital, Bahrain; Tel: +97333884866; Fax: +97333884867; E-mail: drheshamalkhateeb@msn.com


Abstract

We present a retrospective evaluation assessing the use of a novel fibrin sealant, Quixil® (OMRIX Biopharmaceuticals S.A.) in reducing blood transfusions following revision total hip replacement surgery. Forty four patients underwent revision total hip replacement surgery using Quixil®, while 45 patients underwent revision total hip replacement surgery without the use of Quixil®. The duration of surgery and patient demographics were similar in both groups. Average blood loss was 1,010ml in the Quixil® group versus 1,021ml in the non-Quixil group. The use of cell saver and intra-operative blood transfusion were similar in both groups. The mean pre-operative Haemoglobin was 13.0 g/dl in the Quixil® group versus 12.4 g/dl in the non-Quixil group. The mean post-operative haemoglobin was 10.2 g/dl and 9.1 g/dl in the Quixil® and non-Quixil groups respectively. There was no difference in the blood transfused post-operatively between the two groups. Total units of blood transfused in Quixil®versus non-Quixil group were 60 verus 86. Total units of intra-operative blood transfused in Quixil®versus non-Quixil group were 16 versus 23. The use of fibrin tissue adhesive in revision total hip arthroplasty seems to be an effective and reliable means to reduce blood-transfusion requirements and prevent post-operative decreases in hemoglobin.

Keywords: Arthroplasty, blood loss, fibrin glue, revision hip replacement, thrombin fibrin sealant, Quixil .